

From: Phil Baran <pbaran@scripps.edu>
Sent: Friday, February 2, 2024 10:53 AM
To: Edwards, Jeremy
Subject: Fwd: reconnecting

*** EXTERNAL EMAIL - Please use Caution. ***

Exhibit #

2033

02/20/24 JD

Begin forwarded message:

From: <david.butler@hongene.com>
Subject: reconnecting
Date: January 20, 2023 at 11:52:20 AM GMT-3
To: <pbaran@scripps.edu>

Hi Phil,

Happy New Year, I hope you're doing well.

I'm not sure whether you remember me, I used to head the Chemistry group at Wave. You were kind enough to visit us to give a presentation on the P(V) stereodefined chemistry just following publication of the Science paper in 2018. In my opinion, that chemistry, or a variation of it, will eventually be much more widely adopted as the industry and regulators gradually shift from old paradigms and recognize its importance to pharmacology and safety.

I've moved on and am now CTO at Hongene Biotech Corporation – The reason I joined the company is because we are applying new technologies, including stereodefined chemistries, to the development of nucleic acid therapeutics for hundreds of drug sponsors, so there's a lot here to retain my interest, and potential to have a major impact on helping the field bring medicines to patients more quickly and safely.

In one way shape or form I'd love to get you involved in what we're doing at Hongene and am keen to discuss potential opportunities for us to work together if you can spare some time in the coming days.

Please let me know,

Best regards

Dave

David Butler, Ph.D.

Chief Technology Officer
Hongene Biotech Corporation

david.butler@hongene.com

(617)-981-2796

<https://www.hongene.com/>